| JANSSEN-PHARMACEUTICALS-INC |
JANSSEN-PHARMACEUTICALS-INC |
92%
|
The agreements entered into in December 2023 were executed at the same time and were negotiated with a single commercial objective; therefore, they were combined and accounted for as a single contract. |
| PERCEPTIVE-MASTER-FUND |
PERCEPTIVE-MASTER-FUND |
92%
|
MeiraGTx Holdings plc (the “Company”) entered into a share purchase agreement (the “Share Purchase Agreement”) with Perceptive Life Sciences Master Fund, Ltd. (“Perceptive Master Fund”), an affiliate… |
| HOLOGEN |
HOLOGEN |
85%
|
On April 20, 2026 (the "Initial Closing Date"), MeiraGTx Holdings plc (the "Company") and certain of its affiliates completed the initial closing of the strategic collaboration with Hologen Limited, … |
| JOHNSON-JOHNSON-INNOVATIVE-MEDICINE |
JOHNSON-JOHNSON-INNOVATIVE-MEDICINE |
85%
|
MeiraGTx UK II Limited agreed to manufacture and supply the RPGR Product for Johnson & Johnson Innovative Medicine |
| FDMT |
4D Molecular Therapeutics, Inc. |
72%
|
ly. The actual or perceived failure to comply with such obligations could materially harm our business. The global data protection landscape is continually evolving, and we are or may become subjec… |
| FDMT |
4D Molecular Therapeutics, Inc. |
72%
|
Reciprocal relationship from FDMT graph: Reciprocal relationship from MGTX graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from MGTX graph: Reciprocal relationship from FDMT g… |
| JNJ |
Johnson & Johnson |
72%
|
TX HOLDINGS PLC AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS million non-refundable upfront fee from Johnson & Johnson Innovative Medicine and during the year ended December 31, 2021… |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from MGTX graph: TX HOLDINGS PLC AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS million non-refundable upfront fee from … |
| LLY |
Eli Lilly and Company |
72%
|
pecific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute your ownership interest… |
| LLY |
Eli Lilly and Company |
72%
|
Reciprocal relationship from LLY graph: Reciprocal relationship from MGTX graph: pecific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require… |
| SNYNF |
Sanofi |
72%
|
ly. The actual or perceived failure to comply with such obligations could materially harm our business. The global data protection landscape is continually evolving, and we are or may become subjec… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from MGTX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from MGTX graph: ly. The actual or perceived failu… |
| VYGR |
Voyager Therapeutics, Inc. |
72%
|
Reciprocal relationship from VYGR graph: Reciprocal relationship from MGTX graph: Reciprocal relationship from VYGR graph: Reciprocal relationship from MGTX graph: Reciprocal relationship from VYGR g… |
| VYGR |
Voyager Therapeutics, Inc. |
72%
|
ly. The actual or perceived failure to comply with such obligations could materially harm our business. The global data protection landscape is continually evolving, and we are or may become subjec… |
| ASSET-PURCHASE-AGREEMENT-MEIRAGTX-UK-II-LIMITED |
ASSET-PURCHASE-AGREEMENT-MEIRAGTX-UK-II-LIMITED |
62%
|
tend to increase substantially over time, including the ongoing Phase 2 AQUAx2 clinical trial of AAV-hAQP1 for the treatment of patients with radiation-induced xerostomia. In addition, we expect to c… |
| BEACON-THERAPEUTICS-LIMITED |
BEACON-THERAPEUTICS-LIMITED |
62%
|
ly. The actual or perceived failure to comply with such obligations could materially harm our business. The global data protection landscape is continually evolving, and we are or may become subjec… |
| BOFA-SECURITIES-INC |
BOFA-SECURITIES-INC |
62%
|
, $130.0 million from the Collaboration Agreement with Johnson & Johnson Innovative Medicine, $125.0 million from the Asset Purchase Agreement with Johnson & Johnson Innovative Medicine, $50.0 millio… |
| CORPORATE-INFORMATION-MEIRAGTX-HOLDINGS |
CORPORATE-INFORMATION-MEIRAGTX-HOLDINGS |
62%
|
s been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement… |
| COST-BASIS-VISIOGENE-LLC |
COST-BASIS-VISIOGENE-LLC |
62%
|
$ 6,665 December 31, 2024 Investee Investment Type Ownership Percentage Carrying Value Cost Basis Visiogene LLC Equity Method Investment 25.0 % $ 5,133… |
| MEIRAGTX-LIMITED |
MEIRAGTX-LIMITED |
62%
|
pecific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute your ownership interest… |
| MEIRAGTX-OCULAR-UK-LIMITED |
MEIRAGTX-OCULAR-UK-LIMITED |
62%
|
pecific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute your ownership interest… |
| MEIRAGTX-UK-II-LIMITED |
MEIRAGTX-UK-II-LIMITED |
62%
|
asing research and development costs associated with our clinical activities for AAV-GAD for the treatment of Parkinson’s disease, although certain of these increases are expected to be offset by the… |
| MOLECULAR-THERAPEUTICS-INC |
MOLECULAR-THERAPEUTICS-INC |
62%
|
ly. The actual or perceived failure to comply with such obligations could materially harm our business. The global data protection landscape is continually evolving, and we are or may become subjec… |
| PERCEPTIVE-ADVISORS-LLC |
PERCEPTIVE-ADVISORS-LLC |
62%
|
Netherlands as of March 31, 2026. Should the Company determine that it would be able to realize its remaining deferred tax assets in the foreseeable future, an adjustment to its remaining deferred ta… |
| PERCEPTIVE-CREDIT-HOLDINGS |
PERCEPTIVE-CREDIT-HOLDINGS |
62%
|
ic alliances and licensing arrangements. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative… |
| PERCEPTIVE-LIFE-SCIENCES-MASTER-FUND-LTD |
PERCEPTIVE-LIFE-SCIENCES-MASTER-FUND-LTD |
62%
|
re no assurances that we will be successful in obtaining an adequate level of financing for the development and commercialization of our product candidates. We expect to incur significant expenses an… |
| SPARK-THERAPEUTICS-INC |
SPARK-THERAPEUTICS-INC |
62%
|
ly. The actual or perceived failure to comply with such obligations could materially harm our business. The global data protection landscape is continually evolving, and we are or may become subjec… |
| UCL-BUSINESS-LTD |
UCL-BUSINESS-LTD |
62%
|
pecific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute your ownership interest… |
